Concerning Th17-related diseases, the small STAT3 inhibitor STA-21 has been tested on psoriasis patients in a nonrandomized study, and psoriatic lesions in six of the eight patients showed improvement after topical STA-21 treatment for 2 weeks (NCT01047943) (Table 1) (103). This evidence concerns the gene STAT3 and psoriasis.